 economic evaluation lovastatin cholesterol lowering coronary artery disease reduction costs benefits cholesterol lowering primary prevention coronary artery disease CAD lifetime lovastatin therapy intervention model adults years age analysis benefits CAD risk reduction estimates Framingham Heart Study chosen analytic perspective patient average-risk men total serum cholesterol levels mmol/liter mg/dl cost life-year whereas average-risk women cost dollars high-risk men smoking habit hypertension cost life-year saved values whereas high-risk women cost life-year saved values results favorable previous studies alternate medication therapies hypercholesterolemia conservative parameter assumptions years high risk CAD net cost lovastatin therapy medical interventions